EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure

Shazia Ansari, Khadga Raj Aran iD

Cardiovascular Drugs and Therapy · 2026-08 · 40 (4) · 1575-1593

DOI: 10.1007/s10557-025-07830-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 17.01.2026. Verfasst von Shazia Ansari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, ISF College of Pharmacy, Punjab, 142001, Moga, India. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) is a progressive clinical syndrome characterized by structural and functional cardiac impairment, leading to reduced cardiac output, hemodynamic instability, and high morbidity and mortality. Emerging evidence highlights calcitonin gene-related peptide (CGRP) as a crucial regulator of cardiovascular homeostasis, owing to its potent vasodilatory, cardioprotective, anti-inflammatory, and antifibrotic properties. CGRP, predominantly synthesized by sensory neurons, maintains vascular tone, enhances myocardial perfusion, and counteracts maladaptive neurohormonal activation involving the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). In early HF, elevated CGRP levels provide compensatory benefits by reducing afterload, preserving endothelial integrity, and mitigating ventricular remodeling. However, progressive disease stages are characterized by CGRP depletion, receptor downregulation, and impaired signaling, which diminish its protective effects and contribute to pathological fibrosis, hypertrophy, and disruption of the extracellular matrix. Therapeutic strategies targeting CGRP signaling, including peptide agonists, stable analogues such as SAX, gene-based therapies enhancing endogenous CGRP expression, receptor modulators, and TRPV1-induced release stimulators, show promising results in preclinical studies and early-phase clinical studies, demonstrating improved cardiac output, reduced infarct size, and preserved ventricular function. Patients with early-to-mid HF (NYHA I-III), HFpEF with endothelial dysfunction, and hypertension-or-ischemia-driven HF may particularly benefit from CGRP-directed therapies. Conversely, the widespread use of CGRP antagonists for migraine therapy necessitates careful cardiovascular safety evaluation, especially in HF populations. Ongoing clinical trials are exploring CGRP-based interventions are diagnostic biomarkers, personalized therapeutic agents, and disease-modifying treatments. This review consolidates current insights into the physiological and pathophysiological roles of CGRP in HF, evaluates therapeutic opportunities and safety concerns, and discusses future directions, including patient stratification, biomarker-guided precision medicine, and combination regimens. Targeting CGRP pathways holds significant promise for redefining cardiovascular management and improving outcomes in HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideHeart FailureHumansAnimalsSignal TransductionReceptors, Calcitonin Gene-Related Peptide

Stichwörter der Autor:innen

Calcitonin gene-related peptideFibrosisHeart failureNeurohormonal modulationTherapeutic targetingVasodilation

Substanzen

Calcitonin Gene-Related PeptideReceptors, Calcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Department of Pharmacy Practice, ISF College of Pharmacy, Punjab, 142001, Moga, India.
  • Department of Pharmacy Practice, ISF College of Pharmacy, Punjab, 142001, Moga, India. bishalarann@gmail.com.
  • Department of Pharmacology, ISF College of Pharmacy, Punjab, 142001, Moga, India. bishalarann@gmail.com.

ORCID-Profile: Khadga Raj Aran

Zitieren

APA

Ansari, S., & Aran, K. R. (2026). Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure. Cardiovascular Drugs and Therapy, 40(4), 1575-1593. https://doi.org/10.1007/s10557-025-07830-x

Vancouver

Ansari S, Aran KR. Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure. Cardiovascular Drugs and Therapy. 2026;40(4):1575-1593. doi:10.1007/s10557-025-07830-x

BibTeX
@article{Ansari2026,
  author = {Ansari, Shazia and Aran, Khadga Raj},
  title = {Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {1575--1593},
  doi = {10.1007/s10557-025-07830-x}
}
Kostenlos starten →